Search

Author/Creator Glisson, B.S.

1. 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). (September 2015)

Authors:
Pietanza, M.C.; Spigel, D.; Bauer, T.M.; Ready, N.E.; Glisson, B.S.; Morgensztern, D.; Robert, F.; Salgia, R.; Kochendorfer, M.; Patel, M.; Strickland, D.K.; Govindan, R.; Burris, H.A.; Rudin, C.M.; Dylla, S.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S712
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search